Safinamide: all 22 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor FluctuationsRecruitingNCT07761936Phase 3
- A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South KoreaCompletedNCT05312632Phase 4Results posted
- A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese VolunteersCompletedNCT03887221Phase 1Results posted
- A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of LevodopaCompletedNCT03881371Phase 3Results posted
- Effect of Safinamide on Parkinson's Disease Related Chronic PainCompletedNCT03841604Phase 4Results posted
- Safinamide for Multiple System Atrophy (MSA)CompletedNCT03753763Phase 2Results posted
- Safinamide for Levodopa-induced Dyskinesia (PD-LID)WithdrawnNCT03987750Phase 3
- Effect of Safinamide on Sleep Quality in Patients With Parkinson's DiseaseTerminatedNCT03968744Phase 4
- Overnight Switch From Rasagiline To SafinamideCompletedNCT03843944Phase 4
- Safinamide Steady State Interaction With RosuvastatinCompletedNCT03216304Phase 1
- Safinamide Renal Impairment TrialCompletedNCT01374113Phase 1
- 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PDCompletedNCT01286935Phase 3
- A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain ImagingTerminatedNCT01264861Phase 2
- A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's DiseaseCompletedNCT01211587Phase 2
- Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's DiseaseCompletedNCT01187966Phase 3
- Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease SubjectsCompletedNCT01113320Phase 2
- A Study to Assess the Effect of Hepatic Impairment on Safinamide PharmacokineticsCompletedNCT01027169Phase 1
- A Study to Assess the Effect of Safinamide on Levodopa PharmacokineticsCompletedNCT01026428Phase 1/2
- Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease PatientsTerminatedNCT00865579Phase 3
- Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine AgonistCompletedNCT00643045Phase 3
- Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)CompletedNCT00642889Phase 3
- MOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistCompletedNCT00605683Phase 3